Domestic Docetaxel-based combination chemotherapy for patients with metastatic breast cancer.docVIP

 PAGE \* MERGEFORMAT 16 Domestic Docetaxel-based combination chemotherapy for patients with metastatic breast cancer 【Abstract】 Objective To observe the domestic Docetaxel-based combination chemotherapy treatment of metastatic breast cancer, the efficacy, toxicity and clinical benefit response (Clinical benefit response, CBR), and to imports of docetaxel as the control. Methods A group of 30 patients with metastatic breast cancer patients, past did not use anthracycline therapy, 14 cases of use of domestic Docetaxel combined with doxorubicin treatment (A1 group), past anthracycline treatment failure in 16 patients with domestically produced Docetaxel combined with capecitabine in the treatment (A2 group); B group of 25 patients with metastatic breast cancer patients as controls, which did not use anthracycline therapy, 11 cases of imported Docetaxel combined with doxorubicin treatment ( B1 group), past anthracycline treatment failure in 14 cases of imported docetaxel combined with capecitabine in the treatment (B2 group); 3 weeks for one cycle, two cycles were evaluated to record toxicity. Results A group, the effective (CR PR) 66.7%, tumor control rate (CR PR SD) 93.3%. The major toxic reactions were bone marrow suppression and hair loss can be tolerated, no treatment-related death. CBR evaluate effective by 73.3%; B group was 68%, tumor control rate of 92%. A group of toxic side effects and similar. CBR evaluations in force 72%. Conclusion Domestic Docetaxel-based combination chemotherapy for patients with metastatic breast cancer have better efficacy, toxicity can be tolerated, clinical benefit response is good, and imports of docetaxel similar efficacy and adverse reactions. Keywords: Docetaxel; breast cancer; chemical treatment Breast cancer is a common malignancy among women, the incidence rate showed an upward trend year by year. MDT is palliative treatment of metastatic breast cancer means that efficiency by 30% to 80% [1]. Studi